omniture

Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013

2013-02-25 18:00 4102

NANJING, China, February 25, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012 on Thursday, March 7, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, March 7 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

International toll:

+65.6723.9381

United States toll-free:

+1.866.519.4004

United States toll:

+1.718.354.1231

China Domestic toll-free:

800.819.0121

China Domestic mobile toll-free:

400.620.8038

Hong Kong toll:

+852.2475.0994

Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 12783585.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:

+1.855.452.5696

United States toll:

+1.646.254.3697

The passcode for replay participants is 12783585. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com


In Nanjing:





In the United States:

Jie Liu D'Elia




Cindy Zheng


Vice President




Brunswick Group


Simcere Pharmaceutical Group



Tel: 1-212-333-3810

Tel: 86-25-8556-6666*8857














In Beijing:








Yue Yu








Brunswick Group







Tel: 86-10-5960-8600







Source: Simcere Pharmaceutical Group
collection